子分类：
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | E1 ENZYME MUTANTS AND USES THEREOF | US15170328 | 2016-06-01 | US20170107579A1 | 2017-04-20 | Benjamin Stone AMIDON; James E. BROWNELL; James M. GAVIN; Erik M. KOENIG; Michael D. SINTCHAK; Peter G. SMITH |
| The invention provides isolated nucleic acids molecules, designated UBA3, UAE, or UBA6, or other E1 enzyme variant nucleic acid molecules, which encode novel E1 enzyme variant proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing UBA3, UAE, or UBA6, or other E1 enzyme variant nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a UBA3, UAE, or UBA6, or other E1 enzyme variant gene has been introduced or disrupted. The invention still further provides isolated UBA3, UAE, or UBA6, or other E1 enzyme variant proteins, fusion proteins, antigenic peptides and anti-UBA3, UAE, or UBA6, or other E1 enzyme variant antibodies. The invention provides methods to identify agents that inhibit UBA3, UAE, or UBA6, or other E1 enzyme variant expression or activity. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | ||||||
| 2 | E1 ENZYME MUTANTS AND USES THEREOF | US14349843 | 2012-10-05 | US20150030601A1 | 2015-01-29 | Benjamin Stone Amidon; James E. Brownell; James M. Gavin; Erik M. Koenig; Michael D. Sintchak; Peter G. Smith |
| The invention provides isolated nucleic acids molecules, designated UBA3, UAE, or UBA6, or other E1 enzyme variant nucleic acid molecules, which encode novel E1 enzyme variant proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing UBA3, UAE, or UBA6, or other E1 enzyme variant nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a UBA3, UAE, or UBA6, or other E1 enzyme variant gene has been introduced or disrupted. The invention still further provides isolated UBA3, UAE, or UBA6, or other E1 enzyme variant proteins, fusion proteins, antigenic peptides and anti-UBA3, UAE, or UBA6, or other E1 enzyme variant antibodies. The invention provides methods to identify agents that inhibit UBA3, UAE, or UBA6, or other E1 enzyme variant expression or activity. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | ||||||
| 3 | Ｅ１酵素変異体およびその用途 | JP2014534774 | 2012-10-05 | JP2015502137A | 2015-01-22 | ベンジャミン ストーン アミドン，; ジェイムズ ブラウネル，; ジェイムズ エム． ギャビン，; エリック エム． コーニッグ，; マイケル ディー． シンチャック，; ピーター ジー． スミス， |
| 本発明は、UBA3、UAE、もしくはUBA6と名付けられた単離核酸分子、または新規のE1酵素変異体タンパク質をコードする他のE1酵素変異体核酸分子、を提供する。本発明は、アンチセンス核酸分子、UBA3、UAE、もしくはUBA6、または他のE1酵素変異体の核酸分子を含有する組み換え発現ベクター、前記発現ベクターが導入されている宿主細胞、および非UBA3、UAE、もしくはUBA6、または他のE1酵素変異体遺伝子が導入または撹乱されているヒト遺伝子導入動物も提供する。本発明は、単離したUBA3、UAE、もしくはUBA6、または他のE1酵素変異体のタンパク質、融合タンパク質、抗原ペプチドおよび抗UBA3、抗UAE、もしくは抗UBA6抗体、または他のE1酵素変異体に対する抗体もさらに提供する。【選択図】図1 | ||||||
| 4 | E1 ENZYME MUTANTS AND USES THEREOF | EP12838184 | 2012-10-05 | EP2764121A4 | 2015-09-02 | AMIDON BENJAMIN STONE; BROWNELL JAMES; GAVIN JAMES M; KOENIG ERIK M; SINTCHAK MICHAEL D; SMITH PETER G |
| The invention provides isolated nucleic acids molecules, designated UBA3, UAE, or UBA6, or other E1 enzyme variant nucleic acid molecules, which encode novel E1 enzyme variant proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing UBA3, UAE, or UBA6, or other E1 enzyme variant nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a UBA3, UAE, or UBA6, or other E1 enzyme variant gene has been introduced or disrupted. The invention still further provides isolated UBA3, UAE, or UBA6, or other E1 enzyme variant proteins, fusion proteins, antigenic peptides and anti-UBA3, UAE, or UBA6, or other E1 enzyme variant antibodies. The invention provides methods to identify agents that inhibit UBA3, UAE, or UBA6, or other E1 enzyme variant expression or activity. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | ||||||
| 5 | E1 ENZYME MUTANTS AND USES THEREOF | EP12838184.5 | 2012-10-05 | EP2764121A2 | 2014-08-13 | AMIDON, Benjamin, Stone; BROWNELL, James; GAVIN, James, M.; KOENIG, Erik, M.; SINTCHAK, Michael, D.; SMITH, Peter, G. |
| The invention provides isolated nucleic acids molecules, designated UBA3, UAE, or UBA6, or other E1 enzyme variant nucleic acid molecules, which encode novel E1 enzyme variant proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing UBA3, UAE, or UBA6, or other E1 enzyme variant nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a UBA3, UAE, or UBA6, or other E1 enzyme variant gene has been introduced or disrupted. The invention still further provides isolated UBA3, UAE, or UBA6, or other E1 enzyme variant proteins, fusion proteins, antigenic peptides and anti-UBA3, UAE, or UBA6, or other E1 enzyme variant antibodies. The invention provides methods to identify agents that inhibit UBA3, UAE, or UBA6, or other E1 enzyme variant expression or activity. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | ||||||
| 6 | E1 ENZYME MUTANTS AND USES THEREOF | PCT/US2012058983 | 2012-10-05 | WO2013052814A8 | 2014-01-16 | AMIDON BENJAMIN STONE; BROWNELL JAMES; GAVIN JAMES M; KOENIG ERIK M; SINTCHAK MICHAEL D; SMITH PETER G |
| The invention provides isolated nucleic acids molecules, designated UBA3, UAE, or UBA6, or other E1 enzyme variant nucleic acid molecules, which encode novel E1 enzyme variant proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing UBA3, UAE, or UBA6, or other E1 enzyme variant nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a UBA3, UAE, or UBA6, or other E1 enzyme variant gene has been introduced or disrupted. The invention still further provides isolated UBA3, UAE, or UBA6, or other E1 enzyme variant proteins, fusion proteins, antigenic peptides and anti- UBA3, UAE, or UBA6, or other E1 enzyme variant antibodies. The invention provides methods to identify agents that inhibit UBA3, UAE, or UBA6, or other E1 enzyme variant expression or activity. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | ||||||
| 7 | E1 ENZYME MUTANTS AND USES THEREOF | PCT/US2012058983 | 2012-10-05 | WO2013052814A3 | 2013-08-01 | AMIDON BENJAMIN STONE; BROWNELL JAMES; GAVIN JAMES M; KOENIG ERIK M; SINTCHAK MICHAEL D; SMITH PETER G |
| The invention provides isolated nucleic acids molecules, designated UBA3, UAE, or UBA6, or other E1 enzyme variant nucleic acid molecules, which encode novel E1 enzyme variant proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing UBA3, UAE, or UBA6, or other E1 enzyme variant nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a UBA3, UAE, or UBA6, or other E1 enzyme variant gene has been introduced or disrupted. The invention still further provides isolated UBA3, UAE, or UBA6, or other E1 enzyme variant proteins, fusion proteins, antigenic peptides and anti- UBA3, UAE, or UBA6, or other E1 enzyme variant antibodies. The invention provides methods to identify agents that inhibit UBA3, UAE, or UBA6, or other E1 enzyme variant expression or activity. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | ||||||
QQ群二维码
意见反馈
意见反馈